Applied DNA Sciences (APDN, $8.89) gets FDA nod on emergency clinical use of its covid-19 test
Applied DNA Sciences got an authorization from the U.S. Food and Drug Administration (FDA) for emergency clinical use of its covid-19 test, Linea.
"This extraordinary achievement highlights the company’s commitment to combating the covid-19 pandemic both locally and nationwide," Chief Executive James Hayward said in a statement.
The machine that performs the test can process 94 samples per hour and more than 2,000 tests per day. The FDA has authorized emergency use for about 50 molecular tests that can detect COVID-19
Momentum Indicator for BNBX turns negative, indicating new downward trend
BNBX saw its Momentum Indicator move below the 0 level on March 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In of the 78 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNBX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BNBX entered a downward trend on April 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for BNBX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BNBX just turned positive on April 15, 2026. Looking at past instances where BNBX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNBX advanced for three days, in of 155 cases, the price rose further within the following month. The odds of a continued upward trend are .
BNBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.150) is normal, around the industry mean (46.703). P/E Ratio (0.002) is within average values for comparable stocks, (39.709). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.660). Dividend Yield (0.000) settles around the average of (0.083) among similar stocks. P/S Ratio (0.748) is also within normal values, averaging (34.562).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNBX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of botanical deoxyribonucleic acid based security and authentication solutions
Industry InvestmentManagers
Advertisement